Firefly Biologics

Closed

South San Francisco, United States · $94.0M raised

Employees
11–50
Business Model
B2B
Total Funding
$94.0M
Last Round
$94.0M Series AMar 2024
Rounds
1

About

Firefly Bio (dba Firefly Biologics) is a South San Francisco-based biotech developing Degrader Antibody Conjugates (DACs), a new therapeutic class combining the tumor-targeting precision of antibody-drug conjugates with selective protein degrader payloads. The company assembled a leadership team of veteran ADC researchers and is backed by Decheng Capital, MPM BioImpact, and Versant Ventures, having raised a $94 million Series A financing round to advance its pipeline.

Summary

Firefly Biologics is a Biotech company based in South San Francisco, United States. It has raised $94.0M in total across 1 round, most recently a $94.0M Series A round in Mar 2024. Investors include Johnson & Johnson Innovation, Versant Ventures and MPM Capital.

Tech & App Stack

1 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

AcquisitionJun 2026

Sign up to see all 2 rounds

Series A through Acquisition — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Firefly Biologics on Indexed.vc
<a href="https://indexed.vc/companies/firefly-biologics"><img src="https://indexed.vc/api/badge/company/firefly-biologics" alt="Firefly Biologics on Indexed.vc" width="260" height="76" /></a>